Prosensa Holding NV
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.00%171.201.2%$570.55m
CELGCelgene Corporation
-0.36%89.301.2%$561.68m
GILDGilead Sciences, Inc.
-1.33%73.450.9%$442.10m
BIIBBiogen Inc.
-0.61%264.401.2%$434.92m
REGNRegeneron Pharmaceuticals, Inc.
-1.24%311.932.7%$236.68m
INCYIncyte Corporation
-0.80%68.502.5%$229.77m
VRTXVertex Pharmaceuticals Incorporated
-1.12%157.771.9%$220.03m
ALXNAlexion Pharmaceuticals, Inc.
-4.50%106.712.0%$199.08m
NKTRNektar Therapeutics
-1.82%88.516.0%$196.07m
ILMNIllumina, Inc.
-0.13%245.533.5%$181.82m
AAgilent Technologies, Inc.
-0.19%67.841.5%$152.46m
BLUEBluebird Bio, Inc.
-0.24%170.1015.8%$139.94m
ALNYAlnylam Pharmaceuticals, Inc
2.04%98.159.8%$135.20m
EXASExact Sciences Corporation
1.05%47.2925.7%$108.80m
BMRNBioMarin Pharmaceutical Inc.
-2.37%81.644.4%$103.26m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.